SMC accepts Inrebic for treatment of splenomegaly and myelofibrosis

pharmafile | April 12, 2022 | News story | |   

The SMC has accepted Inrebic (fedratinib) for use witin NHS Scotland, for the treatment of disease-related splenomegaly (enlarged spleen).

It is also indicated for adult patients with symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve, or have been treated with ruxolitinib.

Fedratinib is also available on the NHS to eligible patients in England, Wales, and Northern Ireland, following its recommendation by NICE within the Cancer Drugs Fund.

Myelofibrosis is a rare form of blood cancer, affecting the bone marrow and disrupting the body’s normal production of blood cells. Patients with myelofibrosis can experience debilitating symptoms including fatigue, itching, weight loss, night sweats, fever, bone pain, and splenomegaly (enlarged spleen), which can negatively impact their quality of life.

“Until recently patients in Scotland with this rare blood cancer had very few licensed treatment options. We welcome the SMC’s decision to make fedratinib available on the NHS in Scotland, so that patients with myelofibrosis can have access to new treatments to help minimise the severe symptoms of this condition.” said Jonathan Mathias and Nona Baker, Co-Chairs for MPN Voice.

“This is an important milestone for the myelofibrosis community and one that we will be celebrating.”

“Before today, clinicians in Scotland had no approved therapies available on the NHS to manage myelofibrosis in patients who had stopped responding to the current standard of care,” added Dr Mark Drummond, Consultant Haematologist & Honorary Senior lecturer, NHS Greater Glasgow and Clyde. “The SMC decision to make fedratinib available as both a first-line and second-line treatment, is a positive step in broadening the treatment options to help manage this serious condition.”

Lina Adams

Related Content

No items found

Latest content